Simplified detection of Epstein-Barr virus for diagnosis of endemic Burkitt lymphoma

Garner, Andrea L; Álvarez, Julio; Genovese, Caitlyn; Snodgrass, Ryan; Kopparthy, Varun; Erickson, David; Cesarman, Ethel

doi:10.1182/bloodadvances.2022007297

Cited by 3 publications

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The BLENDER could utilize a phase change material within the aluminum heating block to absorb and store excess heat, keeping the system at 65 °C and preventing unwanted overheating which could denature the enzymes. In addition to these mechanical changes, future assay improvements such as a direct-to-LAMP approach 26 could decrease the need for additional processing post-extraction and allow operators to test extracted DNA directly, though more investigation is needed.…”

Section: Conclusion and Discussionmentioning

confidence: 99%

Rapid nucleic acid extraction from skin biopsies using a point-of-care device

McCloskey

Erickson

2022

Lab Chip

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Conclusion and Discussionmentioning

confidence: 99%

Rapid nucleic acid extraction from skin biopsies using a point-of-care device

McCloskey

Erickson

2022

Lab Chip

Self Cite

View full text Add to dashboard Cite

show abstract

Loop-mediated isothermal amplification linked a nanoparticles-based biosensor for detecting Epstein-Barr virus

Yang,

Zeng,

Huang

et al. 2024

Appl Microbiol Biotechnol

View full text Add to dashboard Cite

Epstein-Barr virus (EBV) is a ubiquitous gamma herpesvirus that maintains a lifelong latent association with B lymphocytes. Here, a rapid and reliable diagnosis platform for detecting EBV infection, employing loop-mediated isothermal amplification (LAMP) combined with a gold nanoparticles–based lateral flow biosensors (AuNPs-LFB) (termed LAMP Amplification Mediated AuNPs-LFB Detection, LAMAD), was developed in the current study. A set of specific LAMP primers targeting the Epstein-Barr nuclear antigen (EBNA) leader protein (EBNA-LP) gene was designed and synthesized. Subsequently, these templates extracted from various pathogens and whole blood samples were used to optimize and evaluate the EBV-LAMAD assay. As a result, the limit of detection (LoD) of the EBV-LAMAD assay was 45 copies/reaction. The EBV-LAMAD assay can detect all representative EBV pathogens used in the study, and of note, no cross-reactions were observed with other non-EBV organisms. Moreover, the whole workflow of the EBV-LAMAD assay can be completed within 70 min, including rapid EBV template preparation, EBV-LAMP amplification, and AuNPs-LFB-mediated detection. Taken together, the EBV-LAMAD assay targeting the EBNA-LP gene is a rapid, simplified, sensitive, reliable, and easy-to-use detection protocol that can be used as a competitive potential diagnostic/screening tool for EBV infection in clinical settings, especially in basic laboratories in resource-limited regions. Key points • A novel, simplified, and easy-to-use AuNPs-LFB biosensor was designed and prepared. • LAMP combined with an AuNPs-LFB targeting the novel EBNA-LP gene was established. • EBV-LAMAD is a rapid, sensitive, and reliable detection protocol for EBV infection. Graphical Abstract

show abstract